News about Kymos Group

20 Years Growing Together

The Story of Kymos and PharmaMar: a journey of collaboration and succes Not many companies can celebrate 20 years of collaboration after reporting their best revenues ever and having become a successful multinational group, but contract research organization KYMOS and top biopharmaceutical innovator PHARMAMAR are just going to do that. How the evolution of (...)

By Joan Puig de Dou|2024-08-30T12:03:51+02:00June 28th, 2021|Kymos Group|Comments Off

Pharmaprogress’ real-life cases in AEFI symposium Round Table on Nitrosamines

Pharmaprogress’ real-life cases in AEFI symposium Round Table on Nitrosamines Luca Gramaccioni, Site General Manger at Kymos Pharmaprogress, was a guest speaker at the 40th AEFI symposium last May 11th. He presented “Nitrosamines: How to face the analytical challenges for step 2” at a Round Table alongside other experts from AEMPs, AZIERTA and AGILENT. (...)

By Joan Puig de Dou|2024-08-14T11:13:18+02:00May 10th, 2021|Kymos Group|Comments Off

Your Stability Studies in Safe Hands

In recent years Kymos has experienced a surge in demand from drug manufacturers in need of a reliable outsourcing partner for their stability programmes. Kymos responded by making a major investment to build new climatic chambers in their sites in Spain and Italy to reach today’s 100m³ of storage capacity for all conditions corresponding (...)

By Carles Celma|2024-08-14T11:17:11+02:00April 26th, 2021|CMC, Kymos Group|Comments Off

Kymos wins Biosuccess Award for consolidation and international expansion as science services company

The awards ceremony was held during the CataloniaBio & HealthTech Gala, shared via live streaming. Judit Anido, president of CataloniaBio & HealthTech: “We need more success stories like Kymos. One of the biggest challenges we are facing as a sector is to consolidate the business sphere” Barcelona, 14 October 2020 - CataloniaBio & HealthTech presented (...)

By Joan Puig de Dou|2024-08-14T10:51:40+02:00October 14th, 2020|Kymos Group|Comments Off

Kymos and Prolytic merge to become Kymos Group

With the German CRO joining the European group, Kymos will strengthen its activity in the biologics and advanced therapies market and broaden its services portfolio while offering three local sites in Europe Barcelona, Spain, and Frankfurt, Germany, September 28, 2020 – Kymos S.L. and Prolytic GmbH announce today the completion of a successful strategic (...)

By Joan Puig de Dou|2024-08-14T10:50:29+02:00September 28th, 2020|Kymos Group, News|Comments Off

Biopharmaceutical Global Partners

Meet Pablo Cobo: KYMOS’ key opinion leader in biologics drug development Our head of Biopharmaceutical Testing Pablo Cobo, Chemistry graduate and biologics pioneer, remembers his early days at Ipsen when peptide product development was quite different: “Back in 1994 biopharma companies did most of their development work in-house but because of the high costs of (...)

By Joan Puig de Dou|2024-08-14T10:40:04+02:00September 16th, 2020|Kymos Group|Comments Off

Kymos approval as reference lab for biologics in Lebanon

The Ministry of Public Health of the Republic of Lebanon has approved KYMOS as Reference Laboratory for Biological Drug Tests. This is an important acknowledgement to the efforts undertaken by KYMOS to develop innovative analytical methods for biosimilars and biotechnological products. KYMOS has experience in method development, validation and testing of different biosimilars like infliximab, trastuzumab, pelgastrim or omalizumab; polisaccharides (...)

By Joan Puig de Dou|2024-08-30T12:04:43+02:00March 2nd, 2018|Kymos Group, News|Comments Off